BRCA1 and breast carcinoma: Moreover, it is used in non-operable liposarcomas and leiomyosarcomas [9,10], breast cancer with Breast Cancer type 1 Susceptibility Protein (BRCA1) loss [11], soft-tissue osteosarcoma and has been assessed in a phase II study of extraskeletal myxoid chondrosarcoma and a phase III study of mesenchymal chondrosarcoma [12].